SCHEMBL20587604

SCHEMBL20587604

O=C(NN=Cc1ccc(Br)cc1O)c1cccc(C(F)(F)F)c1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 8/20 0.75
KDM4E B2RXH2 6/20 0.75
LMNA P02545 5/20 0.75
HTT P42858 5/20 0.75
SMN1; SMN2 Q16637 4/20 0.75
TDP1 Q9NUW8 3/20 0.75
PTBP1 P26599 2/20 0.75
POLB P06746 2/20 0.75
MAPT P10636 8/20 0.65
MEN1 O00255 6/20 0.65
HSP90AA1 P07900 2/20 0.58
HPGD P15428 2/20 0.58
GAA P10253 1/20 0.58
ALOX12 P18054 1/20 0.58
KDM1A O60341 3/20 0.53
SIRT1 Q96EB6 1/20 0.53
RAB9A P51151 3/20 0.52
NPC1 O15118 2/20 0.52
MITF O75030 2/20 0.52
L3MBTL1 Q9Y468 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22179617 1.00 KMT2A (0.75) KMT2AKDM4ELMNAHTTSMN1; SMN2
SCHEMBL20587601 1.00 KMT2A (0.75) KMT2AKDM4ELMNAHTTSMN1; SMN2
SCHEMBL6568354 0.88 KMT2A (0.78) KMT2AKDM4ELMNAHTTSMN1; SMN2
SCHEMBL6568357 0.88 KMT2A (0.78) KMT2AKDM4ELMNAHTTSMN1; SMN2
SCHEMBL22179508 0.87 MAPT (0.65) KMT2AKDM4ELMNAHTTSMN1; SMN2
SCHEMBL684556 0.86 KMT2A (1.00) KMT2AKDM4ELMNAHTTSMN1; SMN2
SCHEMBL6571712 0.86 KMT2A (1.00) KMT2AKDM4ELMNAHTTSMN1; SMN2
SCHEMBL6571710 0.86 KMT2A (1.00) KMT2AKDM4ELMNAHTTSMN1; SMN2
SCHEMBL6749902 0.86 KDM4E (0.78) KMT2AKDM4ELMNAHTTSMN1; SMN2
SCHEMBL6749907 0.86 KDM4E (0.78) KMT2AKDM4ELMNAHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12325678-B2 Anti-fungals compounds targeting the synthesis of fungal sphingolipids THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2025-06-10 US disclosed
US-20240124392-A1 ANTI-FUNGALS COMPOUNDS TARGETING THE SYNTHESIS OF FUNGAL SPHINGOLIPIDS THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2024-04-18 US disclosed
US-11858880-B2 Anti-fungals compounds targeting the synthesis of fungal sphingolipids THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2024-01-02 US disclosed
US-20220394973-A1 ANTI-FUNGALS COMPOUNDS TARGETING THE SYNTHESIS OF FUNGAL SPHINGOLIPIDS THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2022-12-15 US disclosed
US-11414378-B2 Anti-fungals compounds targeting the synthesis of fungal sphingolipids THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2022-08-16 US disclosed
US-20200207705-A1 ANTI-FUNGALS COMPOUNDS TARGETING THE SYNTHESIS OF FUNGAL SPHINGOLIPIDS THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2020-07-02 US disclosed
EP-3638649-A1 ANTI-FUNGALS COMPOUNDS TARGETING THE SYNTHESIS OF FUNGAL SPHINGOLIPIDS The Research Foundation for The State University of New York (US) 2020-04-22 EP disclosed
WO-2018232298-A1 ANTI-FUNGALS COMPOUNDS TARGETING THE SYNTHESIS OF FUNGAL SPHINGOLIPIDS THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2018-12-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220394973-A1 ANTI-FUNGALS COMPOUNDS TARGETING THE SYNTHESIS OF FUNGAL SPHINGOLIPIDS ERG28, UGCG, DPM1 KMT2A 3071/4885KDM4E 1377/4885LMNA 3665/4885
US-12325678-B2 Anti-fungals compounds targeting the synthesis of fungal sphingolipids ERG28, UGCG, SMPD1 KMT2A 2770/4885KDM4E 1113/4885LMNA 3582/4885
US-20200207705-A1 ANTI-FUNGALS COMPOUNDS TARGETING THE SYNTHESIS OF FUNGAL SPHINGOLIPIDS ERG28, UGCG, DPM1 KMT2A 3071/4885KDM4E 1377/4885LMNA 3665/4885
US-11858880-B2 Anti-fungals compounds targeting the synthesis of fungal sphingolipids ERG28, UGCG, DPM1 KMT2A 3071/4885KDM4E 1377/4885LMNA 3665/4885
US-20240124392-A1 ANTI-FUNGALS COMPOUNDS TARGETING THE SYNTHESIS OF FUNGAL SPHINGOLIPIDS ERG28, UGCG, DPM1 KMT2A 3071/4885KDM4E 1377/4885LMNA 3665/4885
US-11414378-B2 Anti-fungals compounds targeting the synthesis of fungal sphingolipids ERG28, UGCG, LSS KMT2A 2523/4885KDM4E 1060/4885LMNA 3599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.